SciGlow uses cookies to provide you with a great user experience. By using this website, you agree to the use of cookies on your device.

Nature Materials

Shrey Sindhwani, Abdullah Muhammad Syed, Warren C. W. Chan, Jessica Ngai, Benjamin R. Kingston, Jeremy Rothschild, Presley MacMillan, Yuwei Zhang, Netra Unni Rajesh, Tran Hoang, Jamie L. Y. Wu, Anton Zilman, Ben Ouyang, Zachary Lin (University of Toronto), Laura Maiorino, Mikala Egeblad (Cold Spring Harbor), Stefan Wilhelm (University of Oklahoma), Suresh Gadde, Andrew Sulaiman, Lisheng Wang (University of Ottawa)

University of Toronto

Posted by Jean Ho
Jean covers medicine, wellness, and mental health.

UofT researchers find: Most engineered nanoparticles enter tumours through cells, not between them

University of Toronto researchers have discovered that an active rather than passive process dictates which nanoparticles enter solid tumours, upending decades of thinking in the field of cancer nanomedicine and pointing toward more effective nanotherapies.

1 month ago by University of Toronto

The prevailing theory in cancer nanomedicine — an approach that enables more targeted therapies than standard chemotherapy — has been that nanoparticles mainly diffuse passively into tumours through tiny gaps between cells in the endothelium, which lines the inner wall of blood vessels that support tumour growth.

From left to right: Jessica Ngai, Dr. Shrey Sindhwani, Dr. Abdullah Syed and Benjamin Kingston. Credit: University of Toronto

The researchers previously showed that less than one per cent of nanoparticle-based drugs typically reach their tumour targets. In the current study, they found that among nanoparticles that do penetrate tumours, more than 95 per cent pass through endothelial cells — not between gaps among those cells.

“Our work challenges long-held dogma in the field and suggests a completely new theory,” says Abdullah Syed, a co-lead author on the study and postdoctoral fellow in the lab of Warren Chan, a professor at the Institute of Biomaterials and Biomedical Engineering and the Donnelly Centre for Cellular and Biomolecular Research. “We saw many nanoparticles enter the endothelial cells from blood vessels and exit into the tumour in various conditions. Endothelial cells appear to be crucial gatekeepers in the nanoparticle transport process.”

The journal Nature Materials published the findings.

A transmission emission microscopy image of the endothelial cells surrounding blood vessels. The solid arrows indicate that the nanoparticles (dark spots) are engulfed by the endothelial cells instead of passing through gaps between the cells. Credit: University of Toronto

Syed compares nanoparticles to people trying to get into popular restaurants on a busy night.

“Some restaurants don’t require a reservation, while others have bouncers who check if patrons made reservations,” he says. “The bouncers are a lot more common than researchers thought, and most places only accept patrons with a reservation.”

The researchers established that passive diffusion was not the mechanism of entry with multiple lines of evidence. They took over 400 images of tissue samples from animal models, and saw few endothelial gaps relative to nanoparticles. They observed the same trend using 3D fluorescent imaging and live-animal imaging.

Similarly, they found few gaps between endothelial cells in samples from human cancer patients.

The group then devised an animal model that completely stopped the transportation of nanoparticles through endothelial cells. This allowed them to isolate the contribution of passive transport via gaps between endothelial cells, which proved to be miniscule.

The researchers posit several active mechanisms by which endothelial cells might transport nanoparticles into tumours, including binding mechanisms, intra-endothelial channels and as-yet undiscovered processes, all of which they are investigating.

Meanwhile, the results have major implications for nanoparticle-based therapeutics. “These findings will change the way we think about delivering drugs to tumours using nanoparticles,” says Shrey Sindhwani, also a co-lead author on the paper and an MD/PhD student in the Chan lab. “A better understanding of the nanoparticle transport phenomenon will help researchers design more effective therapies.”

New research explains how HIV avoids getting ZAPped

11 Nov 2019

The research included collaborators from the Department of Physics (University of Toronto), Cold Spring Harbor Laboratory (New York, USA) and the University of Ottawa. The study was funded by the Canada Research Chairs Program, Canadian Cancer Society, Natural Sciences and Engineering Research Council, and Canadian Institutes of Health Research.